Analyst Robert Burns from H.C. Wainwright reiterated a Buy rating on Immix Biopharma and increased the price target to $8.00 from $7.00.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Robert Burns has given his Buy rating due to a combination of factors related to Immix Biopharma’s promising clinical trial results and financial outlook. The updated results from the NEXICART-2 trial, which will be presented at the upcoming ASH meeting, have shown significant efficacy in treating patients with relapsed/refractory AL amyloidosis. The trial demonstrated a 100% response rate and a 70% complete response rate, with no severe adverse events reported, highlighting the potential of NXC-201 as a treatment option where there are currently no FDA-approved therapies.
Additionally, despite reporting a net loss for the third quarter of 2025, Immix Biopharma has maintained a solid cash position, providing a financial runway into the second quarter of 2026. The anticipated data release at the ASH meeting could further strengthen the company’s position, potentially leading to an equity raise. These factors collectively support the Buy rating, reflecting confidence in the company’s strategic direction and potential for future growth.